This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bovie Medical Corporation Reports Results For Three And Nine Months Ended September 30, 2012

Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the third quarter and nine months ended September 30, 2012.

Revenues for the third quarter of fiscal 2012 ended September 30, 2012 increased 6.6% to $6.67 million when compared to $6.26 million in the same period last year. Net loss for the third quarter of fiscal 2012 was $(7,000) or $.00 per diluted share versus net income of $63,000 or $.00 per diluted in the third quarter of fiscal 2011.

For the nine months ended September 30, 2012, revenues increased 8.3% to $20.84 million when compared to $19.25 million in the same period last year. Net income for the first nine months of 2012 was $331,000 or $.02 per diluted share versus $984,000 or $.06 per diluted in the first nine months of fiscal 2011, which included the receipt of a one-time payment of $750,000 as part of a legal settlement agreement in the first nine months of fiscal 2011.

Third quarter revenues were positively impacted by increased electrosurgical generator sales both domestically and internationally as well as increased medical lighting sales compared to the previous year. Gross profit margin increased 1.7% during the quarter mainly attributable to increased sales of higher margin products.

In addition to the condensed statement of operations, which are presented in accordance with GAAP, we have included a pro-forma of income from operations for the nine months ended September 30, 2011, which excludes the legal settlement gain from 2011 for comparative purposes.

J-Plasma™ Update

The Company continues to make progress with the marketing of J-Plasma™. Training of independent sales representatives covering over half of the United States has been completed with additional representatives having been identified for the remainder of the country.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs